Kenta Biotech

Kenta Biotech is is focused on the discovery and development of novel, fully human monoclonal antibodies for the prevention and treatment of serious bacterial and viral infections in the hospital setting. Its MabIgX® technology for the generation and selection of fully human monoclonal antibodies (mAbs) allows the harnessing of the power of the human immune system and transforms it into highly effective therapeutic antibodies for the treatment of life threatening infections.